Cargando…

Abnormal CD13/HLA-DR Expression Pattern on Myeloblasts Predicts Development of Myeloid Neoplasia in Patients With Clonal Cytopenia of Undetermined Significance

OBJECTIVES: Patients with clonal cytopenia of undetermined significance (CCUS) are at increased risk of developing myeloid neoplasia (MN). We evaluated whether a simple flow cytometry immunophenotyping (FCIP) assay could differentiate the risk of development of MN in patients with CCUS. METHODS: Bon...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jevremovic, Dragan, Nanaa, Ahmad, Geyer, Susan M, Timm, Michael, Azouz, Haya, Hengel, Cynthia, Reberg, Alexander, He, Rong, Viswanatha, David, Salama, Mohamad E, Shi, Min, Olteanu, Horatiu, Horna, Pedro, Otteson, Gregory, Greipp, Patricia T, Xie, Zhuoer, Alkhateeb, Hassan B, Hogan, William, Litzow, Mark, Patnaik, Mrinal M, Shah, Mithun, Al-Kali, Aref, Nguyen, Phuong L
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2022
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9535519/ https://www.ncbi.nlm.nih.gov/pubmed/35938646 http://dx.doi.org/10.1093/ajcp/aqac083

Ejemplares similares

Treatment outcome of clonal cytopenias of undetermined significance: a single-institution retrospective study
por: Xie, Zhuoer, et al.
Publicado: (2021)

Clinical and biological characteristics and prognostic impact of somatic GATA2 mutations in myeloid malignancies: a single institution experience
por: Nanaa, Ahmad, et al.
Publicado: (2021)

Therapy-related clonal cytopenia as a precursor to therapy-related myeloid neoplasms
por: Shah, Mithun Vinod, et al.
Publicado: (2022)

P1346: THE IMPACT OF CYTOTOXIC THERAPY ON THE RISK OF PROGRESSION AND DEATH IN PATIENTS WITH CLONAL CYTOPENIA OF UNDETERMINED SIGNIFICANCE.
por: Marissa, LI, et al.
Publicado: (2023)

Observation and treatment in DDX41-mutated acute myeloid leukemia and myelodysplastic syndrome
por: Al-Kali, Aref, et al.
Publicado: (2023)

Genetic features and clinical outcomes of patients with isolated and comutated DDX41-mutated myeloid neoplasms
por: Alkhateeb, Hassan B., et al.
Publicado: (2022)

P734: CLONAL HEIRARCHY AND HETEROGENEITY IN STAG2M MYELOID NEOPLASMS: THE MAYO CLINIC EXPERIENCE
por: Katamesh, Bahga, et al.
Publicado: (2023)

Molecular markers demonstrate diagnostic and prognostic value in the evaluation of myelodysplastic syndromes in cytopenia patients
por: He, Rong, et al.
Publicado: (2022)

P747: CLINICAL CHARACTERISTICS AND OUTCOME OF EZH2-MUTATED MYELOID NEOPLASMS: MAYO CLINIC EXPERIENCE
por: Oum, Muhamad, et al.
Publicado: (2023)

Outcomes of allogeneic transplant in patients with DDX41 mutated myelodysplastic syndrome and acute myeloid leukemia
por: Baranwal, Anmol, et al.
Publicado: (2022)

Clinical and prognostic impact of STAG2 mutations in myeloid neoplasms: the Mayo Clinic experience
por: Katamesh, Bahga, et al.
Publicado: (2022)

S263: CYTOPENIAS, AGE AND CAR-HEMATOTOX SCORE PREDICT THE DEVELOPMENT OF POST CAR T-CELL THERAPY-RELATED MYELOID NEOPLASMS
por: Gurney, Mark, et al.
Publicado: (2023)

P722: CHARACTERISATION OF PHF6 MUTATIONS IN MYELOID NEOPLASMS: THE MAYO CLINIC EXPERIENCE
por: Sai Mittapalli, Amrutha, et al.
Publicado: (2023)

Idiopathic cytopenia of undetermined significance and systemic lupus erythematosus
por: Gonçalves, Romelia Pinheiro, et al.
Publicado: (2013)

U2AF1 pathogenic variants in myeloid neoplasms and precursor states: distribution of co-mutations and prognostic heterogeneity
por: Badar, Talha, et al.
Publicado: (2023)

Acquired erythropoietic uroporphyria associated with clonal cytopenia of undetermined significance
por: Swanson, Leah A., et al.
Publicado: (2022)

P580: CHARACTERISTICS AND OUTCOMES OF PATIENTS WITH WT1 MUTATED MYELOID NEOPLASMS: MAYO CLINIC EXPERIENCE
por: Basmaci, Rami, et al.
Publicado: (2023)

Clinical and molecular correlates of somatic and germline DDX41 variants in patients and families with myeloid neoplasms
por: Badar, Talha, et al.
Publicado: (2023)

Immunophenotypic studies of monoclonal gammopathy of undetermined significance
por: Olteanu, Horatiu, et al.
Publicado: (2008)

Structural aberrations are associated with poor survival in patients with clonal cytopenia of undetermined significance
por: Mikkelsen, Stine U., et al.
Publicado: (2020)

Utility of flow cytometry screening before MRD testing in multiple myeloma
por: Panakkal, Vandana, et al.
Publicado: (2023)

LEP promoter methylation in the initiation and progression of clonal cytopenia of undetermined significance and myelodysplastic syndrome
por: Kaastrup, Katja, et al.
Publicado: (2023)

Classification of Monocytes, Promonocytes and Monoblasts Using Deep Neural Network Models: An Area of Unmet Need in Diagnostic Hematopathology
por: Osman, Mazen, et al.
Publicado: (2021)

Myelodysplastic syndrome versus idiopathic cytopenia of undetermined significance: the role of morphology in distinguishing between these entities
por: dos Santos, Talyta Ellen de Jesus, et al.
Publicado: (2013)

Artificial Intelligence Enhances Diagnostic Flow Cytometry Workflow in the Detection of Minimal Residual Disease of Chronic Lymphocytic Leukemia
por: Salama, Mohamed E., et al.
Publicado: (2022)

High EASIX score is an independent predictor of non-relapse mortality in patients with CMML undergoing allogeneic stem cell transplant
por: Baranwal, Anmol, et al.
Publicado: (2022)

Daunorubicin-60 versus daunorubicin-90 versus idarubicin-12 for induction chemotherapy in acute myeloid leukemia: a retrospective analysis of the Mayo Clinic experience
por: Tefferi, Ayalew, et al.
Publicado: (2022)

Inflammatory Cytokine Profiles Do Not Differ Between Patients With Idiopathic Cytopenias of Undetermined Significance and Myelodysplastic Syndromes
por: Nielsen, Amalie Bach, et al.
Publicado: (2022)

Emerging Role of T-cell Receptor Constant β Chain-1 (TRBC1) Expression in the Flow Cytometric Diagnosis of T-cell Malignancies
por: Horna, Pedro, et al.
Publicado: (2021)

Molecular predictors of response to venetoclax plus hypomethylating agent in treatment-naïve acute myeloid leukemia
por: Gangat, Naseema, et al.
Publicado: (2022)

Clinical outcome of myelodysplastic syndrome progressing on hypomethylating agents with evolving frontline therapies: continued challenges and unmet needs
por: Ghorab, Ahmad, et al.
Publicado: (2022)

Adverse karyotype subcategories in acute myeloid leukemia display significant differences in mutation composition and transplant-augmented survival
por: Tefferi, Ayalew, et al.
Publicado: (2022)

Salvage use of venetoclax-based therapy for relapsed AML post allogeneic hematopoietic cell transplantation
por: Joshi, Maansi, et al.
Publicado: (2021)

Therapy-related myeloid neoplasms following chimeric antigen receptor T-cell therapy for Non-Hodgkin Lymphoma
por: Alkhateeb, Hassan B., et al.
Publicado: (2022)

Adult acute megakaryoblastic leukemia: rare association with cytopenias of undetermined significance and p210 and p190 BCR–ABL transcripts
por: Dima, Delia, et al.
Publicado: (2017)

Unique ethnic features of DDX41 mutations in patients with idiopathic cytopenia of undetermined significance, myelodysplastic syndrome, or acute myeloid leukemia
por: Choi, Eun-Ji, et al.
Publicado: (2021)

Clonal Cytopenia of Undetermined Significance in a Patient with Congenital Wilms' Tumor 1 and Acquired DNMT3A Gene Mutations
por: Murakami, Ken, et al.
Publicado: (2021)

Abnormal karyotype is an independent predictor of inferior survival in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
por: Abdallah, Mostafa, et al.
Publicado: (2023)

Cardiac events in patients with acute myeloid leukemia treated with venetoclax combined with hypomethylating agents
por: Johnson, Isla M., et al.
Publicado: (2022)

Outcome of patients with acute myeloid leukemia following failure of frontline venetoclax plus hypomethylating agent therapy
por: Gangat, Naseema, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_39cml9rm0ut7c9eesapiode100